Samuele Gherardi

Ferrara, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications

Reduced menin expression leads to decreased ERα expression and is correlated with the occurrence of human luminal B-like and ER-negative breast cancer subtypes.

Reduced menin expression leads to decreased ERα expression and is correlated with the occurrence of human luminal B-like and ER-negative breast cancer subtypes.

Journal: Breast cancer research and treatment
Published: March 02, 2021

Corrigendum to: "Transcriptional and epigenetic analyses of the DMD locus reveal novel cis-acting DNA elements that govern muscle dystrophin expression". [Biochim. Biophys. Acta Gene Regul. Mech. 2017 Nov;1860(11):1138-1147.].

Corrigendum to: "Transcriptional and epigenetic analyses of the DMD locus reveal novel cis-acting DNA elements that govern muscle dystrophin expression". [Biochim. Biophys. Acta Gene Regul. Mech. 2017 Nov;1860(11):1138-1147.].

Journal: Biochimica et biophysica acta. Gene regulatory mechanisms
Published: November 04, 2020

Men1 disruption in Nkx3.1-deficient mice results in ARlow/CD44+ microinvasive carcinoma development with the dysregulated AR pathway.

Men1 disruption in Nkx3.1-deficient mice results in ARlow/CD44+ microinvasive carcinoma development with the dysregulated AR pathway.

Journal: Oncogene
Published: June 05, 2020

Transcriptional and epigenetic analyses of the DMD locus reveal novel cis‑acting DNA elements that govern muscle dystrophin expression.

Transcriptional and epigenetic analyses of the DMD locus reveal novel cis‑acting DNA elements that govern muscle dystrophin expression.

Journal: Biochimica et biophysica acta. Gene regulatory mechanisms
Published: May 09, 2017

Menin regulates Inhbb expression through an Akt/Ezh2-mediated H3K27 histone modification.

Menin regulates Inhbb expression through an Akt/Ezh2-mediated H3K27 histone modification.

Journal: Biochimica et biophysica acta. Gene regulatory mechanisms
Published: October 28, 2016

MYCN promotes neuroblastoma malignancy by establishing a regulatory circuit with transcription factor AP4.

MYCN promotes neuroblastoma malignancy by establishing a regulatory circuit with transcription factor AP4.

Journal: Oncotarget
Published: January 11, 2016

Foxa2, a novel protein partner of the tumour suppressor menin, is deregulated in mouse and human MEN1 glucagonomas.

Foxa2, a novel protein partner of the tumour suppressor menin, is deregulated in mouse and human MEN1 glucagonomas.

Journal: The Journal of pathology
Published: September 11, 2015

WDR5 Supports an N-Myc Transcriptional Complex That Drives a Protumorigenic Gene Expression Signature in Neuroblastoma.

WDR5 Supports an N-Myc Transcriptional Complex That Drives a Protumorigenic Gene Expression Signature in Neuroblastoma.

Journal: Cancer research
Published: February 12, 2015

MYCN amplification confers enhanced folate dependence and methotrexate sensitivity in neuroblastoma.

MYCN amplification confers enhanced folate dependence and methotrexate sensitivity in neuroblastoma.

Journal: Oncotarget
Published: February 10, 2015

SKP2 is a direct transcriptional target of MYCN and a potential therapeutic target in neuroblastoma.

SKP2 is a direct transcriptional target of MYCN and a potential therapeutic target in neuroblastoma.

Journal: Cancer letters
Published: January 20, 2015

Physical interaction between MYCN oncogene and polycomb repressive complex 2 (PRC2) in neuroblastoma: functional and therapeutic implications.

Physical interaction between MYCN oncogene and polycomb repressive complex 2 (PRC2) in neuroblastoma: functional and therapeutic implications.

Journal: The Journal of biological chemistry
Published: January 31, 2013

MYCN-mediated transcriptional repression in neuroblastoma: the other side of the coin.

MYCN-mediated transcriptional repression in neuroblastoma: the other side of the coin.

Journal: Frontiers in oncology
Published: December 14, 2012
Showing 1-12 of 14

Last Updated: 09/26/2026